Trials / Terminated
TerminatedNCT04521296
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo
A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase II/III Study to Evaluate the Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 432 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety after administration of DWJ1248 in patients with mild to moderate COVID-19 compared to the placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Part 1 | \- DWJ1248 600mg PO (100mg 2 tab, TID) |
| OTHER | Part 2 | \- DWJ1248 600mg PO (200mg 1 tab, TID) |
Timeline
- Start date
- 2020-09-11
- Primary completion
- 2021-09-14
- Completion
- 2022-03-18
- First posted
- 2020-08-20
- Last updated
- 2022-06-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04521296. Inclusion in this directory is not an endorsement.